Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients

Calderón‐Domínguez, María; Trejo, Eva; González-Rovira, Almudena; Beltrán-Camacho, Lucía; Rojas-Torres, Marta; Eslava-Alcon, Sara; Sánchez-Morillo, Daniel; Calderon-Dominguez, Juan; Martinez-Nicolás, Mª Pilar; Gonzalez-Beitia, Estibaliz; Nieto-Martín, Ma Dolores; Trujillo-Soto, Teresa; Rodríguez-Iglesias, Manuel; Moreno, Juan Antonio; Moreno‐Luna, Rafael; Durán-Ruiz, Ma Carmen

doi:10.1016/j.omtn.2022.06.006

Cited by 22 publications

(24 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, hsa-miR-1246 has not only been identified as a possible regulator of the SARS-CoV-2 genome, but also targets ACE2 [49]. Moreover, ACE2 mRNA level is inversely proportional to miR-1246 level in airway epithelial cells of smokers [31].…”

Section: Differential Expression Of Circulating Mirnas In Sars-cov-2 ...mentioning

confidence: 99%

“…The hypersensitivity of circulating miRNAs was also observed in asymptomatic patients. Calderon-Dominguez et al showed that serum hsa-miR-32-5p and hsa-miR-1246 could significantly discriminate between critical COVID-19 patients and asymptomatic IgG-positive individuals 49 . Both of them target the RAB14 gene and that are associated with risk factors (obesity, AHT, T2D, asthma and Thalassemia) in critical COVID-19 patients 49 .…”

Section: Differential Expression Of Circulating Mirnas In Sars-cov-2 ...mentioning

confidence: 99%

“…Calderon-Dominguez et al showed that serum hsa-miR-32-5p and hsa-miR-1246 could significantly discriminate between critical COVID-19 patients and asymptomatic IgG-positive individuals 49 . Both of them target the RAB14 gene and that are associated with risk factors (obesity, AHT, T2D, asthma and Thalassemia) in critical COVID-19 patients 49 . Additionally, hsa-miR-1246 has not only been identified as a possible regulator of the SARS-CoV-2 genome, but also targets ACE2 49 .…”

Section: Differential Expression Of Circulating Mirnas In Sars-cov-2 ...mentioning

confidence: 99%

See 2 more Smart Citations

Circulating microRNAs as emerging regulators of COVID-19

Liang¹,

Fang²,

Gao³

et al. 2023

Theranostics

View full text Add to dashboard Cite

Coronavirus disease 2019 , an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic that has high incidence rates, spreads rapidly, and has caused more than 6.5 million deaths globally to date. Currently, several drugs have been used in the clinical treatment of COVID-19, including antivirals (e.g., molnupiravir, baricitinib, and remdesivir), monoclonal antibodies (e.g., etesevimab and tocilizumab), protease inhibitors (e.g., paxlovid), and glucocorticoids (e.g., dexamethasone). Increasing evidence suggests that circulating microRNAs (miRNAs) are important regulators of viral infection and antiviral immune responses, including the biological processes involved in regulating COVID-19 infection and subsequent complications. During viral infection, both viral genes and host cytokines regulate transcriptional and posttranscriptional steps affecting viral replication. Virus-encoded miRNAs are a component of the immune evasion repertoire and function by directly targeting immune functions. Moreover, several host circulating miRNAs can contribute to viral immune escape and play an antiviral role by not only promoting nonstructural protein (nsp) 10 expression in SARS coronavirus, but among others inhibiting NOD-like receptor pyrin domain-containing (NLRP) 3 and IL-1β transcription. Consequently, understanding the expression and mechanism of action of circulating miRNAs during SARS-CoV-2 infection will provide unexpected insights into circulating miRNA-based studies. In this review, we examined the recent progress of circulating miRNAs in the regulation of severe inflammatory response, immune dysfunction, and thrombosis caused by SARS-CoV-2 infection, discussed the mechanisms of action, and highlighted the therapeutic challenges involving miRNA and future research directions in the treatment of COVID-19.

show abstract

Section: Differential Expression Of Circulating Mirnas In Sars-cov-2 ...mentioning

confidence: 99%

Section: Differential Expression Of Circulating Mirnas In Sars-cov-2 ...mentioning

confidence: 99%

Section: Differential Expression Of Circulating Mirnas In Sars-cov-2 ...mentioning

confidence: 99%

See 1 more Smart Citation

Circulating microRNAs as emerging regulators of COVID-19

Liang¹,

Fang²,

Gao³

et al. 2023

Theranostics

View full text Add to dashboard Cite

show abstract

“…Khan et al [ 59 ] reported that during SARS-CoV-2 infection host miRNAs may downregulate the signaling of different TLRs, which play a fundamental stimulatory role in inducing the host antiviral activity (i.e., secretion of interferons and other inflammatory cytokines). A recent in silico study showed that six host miRNAs (hsa-miR-32-5p, hsa-miR-98-3p, hsa-miR-214-3p, hsa-miR-421, hsa-miR-423-3p, and hsa-miR-1246) can target ACE2 and TMPRSS2 and the number of binding sites of hsa-miR-98-3p and hsa-miR-423-3p was the highest (a match of 6 nucleotides) [ 124 ]. These miRNAs were found to increase in critical COVID-19 patients.…”

Section: Ability Of Sars-cov-2 Escaping the Host Immune System Throug...mentioning

confidence: 99%

“…These miRNAs were found to increase in critical COVID-19 patients. In addition, a functional analysis showed that the target genes are involved in the viral process, including viral RNA replication and viral entry into the host nucleus or regulation of the viral genome replication [ 124 ].…”

Section: Ability Of Sars-cov-2 Escaping the Host Immune System Throug...mentioning

confidence: 99%

miRNAs: The Key Regulator of COVID-19 Disease

Hardin

Xiao

2022

International Journal of Cell Biology

View full text Add to dashboard Cite

As many parts of the world continue to fight the innumerable waves of COVID-19 infection, SARS-CoV-2 continues to sculpt its antigenic determinants to enhance its virulence and evolvability. Several vaccines were developed and used around the world, and oral antiviral medications are being developed against SARS-CoV-2. However, studies showed that the virus is mutating in line with the antibody’s neutralization escape; thus, new therapeutic alternatives are solicited. We hereby review the key role that miRNAs can play as epigenetic mediators of the cross-talk between SARS-CoV-2 and the host cells. The limitations resulting from the “virus intelligence” to escape and antagonize the host miRNAs as well as the possible mechanisms that could be used in the viral evasion strategies are discussed. Lastly, we suggest new therapeutic approaches based on viral miRNAs.

show abstract

Exosomes, and the potential for exosome‐based interventions against COVID‐19

Rahmani,

Soleymani,

Almukhtar

et al. 2024

Reviews in Medical Virology

View full text Add to dashboard Cite

Since late 2019, the world has been devastated by the coronavirus disease 2019 (COVID‐19) induced by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), with more than 760 million people affected and ∼seven million deaths reported. Although effective treatments for COVID‐19 are currently limited, there has been a strong focus on developing new therapeutic approaches to address the morbidity and mortality linked to this disease. An approach that is currently being investigated is the use of exosome‐based therapies. Exosomes are small, extracellular vesicles that play a role in many clinical diseases, including viral infections, infected cells release exosomes that can transmit viral components, such as miRNAs and proteins, and can also include receptors for viruses that facilitate viral entry into recipient cells. SARS‐CoV‐2 has the ability to impact the formation, secretion, and release of exosomes, thereby potentially facilitating or intensifying the transmission of the virus among cells, tissues and individuals. Therefore, designing synthetic exosomes that carry immunomodulatory cargo and antiviral compounds are proposed to be a promising strategy for the treatment of COVID‐19 and other viral diseases. Moreover, exosomes generated from mesenchymal stem cells (MSC) might be employed as cell‐free therapeutic agents, as MSC‐derived exosomes can diminish the cytokine storm and reverse the suppression of host anti‐viral defences associated with COVID‐19, and boost the repair of lung damage linked to mitochondrial activity. The present article discusses the significance and roles of exosomes in COVID‐19, and explores potential future applications of exosomes in combating this disease. Despite the challenges posed by COVID‐19, exosome‐based therapies could represent a promising avenue for improving patient outcomes and reducing the impact of this disease.

show abstract

Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients

Cited by 22 publications

References 58 publications

Circulating microRNAs as emerging regulators of COVID-19

Circulating microRNAs as emerging regulators of COVID-19

miRNAs: The Key Regulator of COVID-19 Disease

Exosomes, and the potential for exosome‐based interventions against COVID‐19

Contact Info

Product

Resources

About